Lightstone Ventures

Lightstone Ventures, founded in 2012, is a venture capital firm that focuses on early-stage investments in the life sciences sector. The firm is based in Menlo Park, California, with additional offices in Boston and Dublin. Lightstone Ventures has a strong track record of investing in biopharmaceutical and medical device companies. Notable investments by Lightstone Ventures include companies such as Reprieve Cardiovascular, which focuses on innovative treatments for heart failure, and Carrick Therapeutics, a biopharmaceutical company developing treatments for cancer. Another significant investment is in Catamaran Bio, which is advancing cell therapies for cancer. The firm recently closed its third fund at $375 million, which will be used to support early-stage companies developing high-impact therapeutics and technologies. Lightstone Ventures' investment strategy emphasizes translating novel scientific breakthroughs into clinically and commercially meaningful therapies. This approach has resulted in successful exits, such as Ra Pharmaceuticals and Disarm Therapeutics, highlighting their ability to nurture companies from inception to market success.